⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
prnewswire.com
VNDA
ANAB
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
prnewswire.com
VNDA